| ELEDON PHARMACEUT.DL-,001 |
| USA |
| Gesundheit |
| US28617K1016 / A2QL00 |
| 2TK (Frankfurt) / ELDN (NASDAQ) |
| FRA:2TK, ETR:2TK, 2TK:GR, NASDAQ:ELDN |
| - |
| https://eledon.com/ |
|
Eledon Pharmaceuticals is a clinical-stage biotechnology company focused on developing immune-modulating therapies for transplantation, autoimmune diseases, and neurodegenerative conditions. The company's lead investigational product is tegoprubart, ..
>Volltext.. |
| 246.8 Mio. EUR |
| 181 Mio. EUR |
| - |
| -70.91 Mio. EUR |
| -38.85 Mio. EUR |
| -0.51 EUR |
| 0.55 Mio. EUR |
| 19.43 Mio. EUR |
| - |
| 7.27 |
| - |
| 31.53% |
| - |
| - |
| - |
| - |
| ELEDON |
| 13.05.26 |
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|